Harris Benjamin S, Hopkins Maeve K, Villers Margaret S, Weber Jeremy M, Pieper Carl, Grotegut Chad A, Swamy Geeta K, Hughes Brenna L, Heine R Phillips
Department of Obstetrics and Gynecology, Duke University Health System, Durham, North Carolina.
Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Duke University Health System, Durham, North Carolina.
AJP Rep. 2019 Apr;9(2):e167-e171. doi: 10.1055/s-0039-1685503. Epub 2019 Apr 30.
To examine the association between perioperative Beta ( ))-lactam versus non- -lactam antibiotics and cesarean delivery surgical site infection (SSI). Retrospective cohort of women undergoing cesarean delivery from January 1 to December 31, 2014. All women undergoing cesarean after 34 weeks with a postpartum visit were included. Prevalence of SSI was compared between women receiving -lactam versus non- -lactam antibiotics. Bivariate analyses were performed using Pearson's Chi-square, Fisher's exact, or Wilcoxon's rank-sum tests. Logistic regression models were fit controlling for possible confounders. Of the 929 women included, 826 (89%) received -lactam prophylaxis and 103 (11%) received a non- -lactam. Among the 893 women who reported a non-type I (low risk) allergy, 819 (92%) received -lactam prophylaxis. SSI occurred in 7% of women who received -lactam antibiotics versus 15% of women who received a non- -lactam ( = 0.004). -Lactam prophylaxis was associated with lower odds of SSI compared with non- -lactam antibiotics (odds ratio [OR] = 0.43; 95% confidence interval [CI] = 0.22-0.83; = 0.01) after controlling for chorioamnionitis in labor, postlabor cesarean, endometritis, tobacco use, and body mass index (BMI). -Lactam perioperative prophylaxis is associated with lower odds of a cesarean delivery surgical site infection compared with non- -lactam antibiotics.
探讨围手术期β(β)-内酰胺类抗生素与非β-内酰胺类抗生素与剖宫产手术部位感染(SSI)之间的关联。
回顾性队列研究2014年1月1日至12月31日接受剖宫产的女性。纳入所有孕周34周后行剖宫产且有产后访视的女性。比较接受β-内酰胺类抗生素与非β-内酰胺类抗生素的女性中SSI的发生率。采用Pearson卡方检验、Fisher精确检验或Wilcoxon秩和检验进行双变量分析。拟合逻辑回归模型以控制可能的混杂因素。
在纳入的929名女性中,826名(89%)接受了β-内酰胺类预防性用药,103名(11%)接受了非β-内酰胺类预防性用药。在报告无I型(低风险)过敏的893名女性中,819名(92%)接受了β-内酰胺类预防性用药。接受β-内酰胺类抗生素的女性中7%发生了SSI,而接受非β-内酰胺类抗生素的女性中这一比例为15%(P = 0.004)。在控制了产时绒毛膜羊膜炎、产后剖宫产、子宫内膜炎、吸烟和体重指数(BMI)后,与非β-内酰胺类抗生素相比,β-内酰胺类预防性用药与较低的SSI发生几率相关(优势比[OR]=0.43;95%置信区间[CI]=0.22 - 0.83;P = 0.01)。
与非β-内酰胺类抗生素相比,围手术期β-内酰胺类预防性用药与较低的剖宫产手术部位感染几率相关。